Documents

Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.

2026

Earnings, Q1 FY2026

Apr 29, 2026

Strong R&D advances and improved funding position support future growth despite Q1 losses.

2025

Earnings, Q4 FY2025

Feb 19, 2026

Transformative Moderna deal, improved financials, and strong depot GLP-1 results drive outlook.

Earnings, Q3 FY2025

Nov 6, 2025

Major partnership extended, patent granted, and funding secured amid revenue decline.

Earnings, Q2 FY2025

Aug 27, 2025

NEX-22 Phase I results support once-monthly dosing; financials show extended runway to Q1 2026.

Earnings, Q1 FY2025

May 6, 2025

NEX-22 clinical progress and new financing position Nanexa for growth despite Q1 losses.

2024

Earnings, Q4 FY2024

Feb 19, 2025

Positive phase I results for NEX-22 and strengthened liquidity position Nanexa for 2025 growth.

Earnings, Q3 FY2024

Nov 7, 2024

NEX-22 Phase I completed; losses narrowed, but further financing is required.

Earnings, Q2 FY2024

Aug 27, 2024

NEX-22 clinical trial launched; losses narrowed, but new funding required within a year.

Earnings, Q1 FY2024

May 3, 2024

2023

Earnings, Q4 FY2023

Feb 21, 2024

Earnings, Q3 FY2023

Nov 20, 2023

Earnings, Q2 FY2023

Aug 23, 2023

Earnings, Q1 FY2023

May 4, 2023

2022

Earnings, Q4 FY2022

Feb 16, 2023

Earnings, Q3 FY2022

Oct 25, 2022

Earnings, Q1 FY2022

Apr 20, 2022

2021

Earnings, Q4 FY2021

Feb 17, 2022

Earnings, Q3 FY2021

Nov 10, 2021

Earnings, Q2 FY2021

Aug 20, 2021

Business Update

Jun 17, 2021

Nanexa AB

Documents